# PharmaCyte Biotech, Inc.: Form 10-Q/A for the period ended Jan 31, 2017

- Company: [PharmaCyte Biotech, Inc.](/companies/pmcb.md) (CIK 1157075)
- Form: 10-Q/A
- Filed: 2017-03-13
- Accepted by EDGAR: Mar 13, 2017, 08:38 ET
- Period: 2017-01-31
- Accession: 0001683168-17-000544
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1157075/000168316817000544/pharmacyte_10qa-013117.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1157075/000168316817000544/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-01-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-11-01 to 2017-01-31 | $0 | us-gaap:Revenues |
| Revenue | 9 months, 2016-05-01 to 2017-01-31 | $0 | us-gaap:Revenues |
| Cost of revenue | 3 months, 2016-11-01 to 2017-01-31 | $0 | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2016-05-01 to 2017-01-31 | $0 | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2016-11-01 to 2017-01-31 | $0 | us-gaap:GrossProfit |
| Gross profit | 9 months, 2016-05-01 to 2017-01-31 | $0 | us-gaap:GrossProfit |
| Research and development | 3 months, 2016-11-01 to 2017-01-31 | $579.7k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2016-05-01 to 2017-01-31 | $1.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2016-11-01 to 2017-01-31 | −$1.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2016-05-01 to 2017-01-31 | −$3.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2016-11-01 to 2017-01-31 | $131 | us-gaap:InterestExpense |
| Interest expense | 9 months, 2016-05-01 to 2017-01-31 | $1.1k | us-gaap:InterestExpense |
| Net income | 3 months, 2016-11-01 to 2017-01-31 | −$1.3m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2016-05-01 to 2017-01-31 | −$3.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-11-01 to 2017-01-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2016-05-01 to 2017-01-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted shares (weighted) | 3 months, 2016-11-01 to 2017-01-31 | 859,529,933 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2016-05-01 to 2017-01-31 | 832,203,911 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Cash and equivalents | at 2017-01-31 | $2.5m | us-gaap:Cash |
| Current assets | at 2017-01-31 | $2.5m | us-gaap:AssetsCurrent |
| Total assets | at 2017-01-31 | $7.6m | us-gaap:Assets |
| Current liabilities | at 2017-01-31 | $578.3k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-01-31 | $578.3k | us-gaap:Liabilities |
| Shareholders' equity | at 2017-01-31 | $7.0m | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1157075/000168316817000544/pharmacyte_10qa-013117.htm

Filed Mar 13, 2017.
Source: SEC EDGAR, the filing index for accession 0001683168-17-000544. Last ingested by Listed: Nov 14, 2026, 20:52 ET. No prices; not investment advice.
